BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2023

View Archived Issues
HIV-1 virus particle

Düsseldorf patient cured of HIV after stem cell transplant

Fifteen years ago, at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI), researchers announced that they had cured a patient – Timothy Ray Brown, initially known only as the Berlin Patient to preserve his privacy – of HIV through a hematopoietic stem cell transplant. Now, as researchers are gathered in Seattle for CROI 2023, reports of another cured patient were published Feb. 20, 2023, in Nature Medicine. Ten years after receiving a hematopoietic stem cell transplant, and 4 years after stopping antiretroviral treatment (ART), a 53-year-old patient may have been cured of HIV infection. Read More

Targeting CD70 could overcome EGFR-TKI resistance in non-small-cell lung cancer

The development of EGFR-targeted tyrosine kinase inhibitors (TKIs) over the past 20 years has modestly improved progression-free survival for patients with metastatic NSCLC. But many patients with EGFR mutations fail to respond to TKI treatments, and immune checkpoint inhibitors elicit a response in less than 10% of NSCLC patients. Read More
Melanoma cells stained with an H & E stain and magnified to 320x.

New iridium(III) complexes show efficacy in preclinical models of cancer

Researchers from Guangdong Pharmaceutical University presented the discovery of novel iridium(III) complexes as potential anticancer agents. Read More
Illustration demonstrating parts of the ear

CEP250 gene variant found behind non-syndromic hearing loss

The CEP250 gene encodes centrosome-associated protein CEP250, involved in the formation of active centrosome components and cell cycle progression. CEP250 has been previously implicated in atypical Usher syndrome, which is characterized by early-onset hearing loss and mild retinitis pigmentosa. Read More
Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Meflin as predictive marker for response to ICI in clear cell renal cell carcinoma

Previous studies revealed that cancer-restraining cancer-associated fibroblasts express Meflin as a marker in pancreatic cancer, and further research has shown that Meflin can also be a good predictive marker for immune checkpoint inhibitor (ICI) response in non-small-cell lung cancer. Read More
Lab mouse

WFS1 gene plays crucial roles in cochlear maintenance and hair cell survival, murine model shows

Wolfram syndrome is a neurodegenerative disease characterized by neurological symptoms, as well as diabetes, optic atrophy and hearing loss, among others. The WFS1 gene encodes a protein named Wolframin and it accounts for about 99% of cases, 60% of which present with hearing loss. To date, of all animal models of Wolfram syndrome developed carrying a variant or deletion of one exon of Wfs1, none mimics the early-onset hearing loss. Read More

Novartis patents new neuraminidase inhibitors for influenza

Novartis AG has disclosed neuraminidase inhibitors acting as viral replication inhibitors reported to be useful for the treatment of influenza. Read More
Escherichia-Coli-bacteria.png

French researchers divulge new efflux pump inhibitors for gram-negative bacterial infections

Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, INSERM and Institut Pasteur de Lille have synthesized efflux pump inhibitors reported to be useful for the treatment of gram-negative bacterial infections. Read More

Theranocure presents MRI contrast agents for use in Alzheimer's and Parkinson's diseases

Theranocure Co. Ltd. has divulged gadolinium complexes targeting β-amyloid protein acting as magnetic resonance imaging (MRI) contrast agents reported to be useful for the diagnosis of Alzheimer's disease and the treatment of Parkinson's and Alzheimer's disease. Read More

Chinese researchers discover new SOS1 inhibitors

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have described pyrimidocyclic derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndrome. Read More
Lungs and bronchi

Rijksuniversiteit Groningen describes new HDAC inhibitors

Rijksuniversiteit Groningen has identified histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, small cell and non-small-cell lung cancer (NSCLC). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing